Segui
Stéphane Epelbaum
Stéphane Epelbaum
International Leader Neuroscience - Eli Lilly
Email verificata su lilly.com
Titolo
Citata da
Citata da
Anno
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
B Dubois, HH Feldman, C Jacova, H Hampel, JL Molinuevo, K Blennow, ...
The Lancet Neurology 13 (6), 614-629, 2014
37422014
Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria
B Dubois, H Hampel, HH Feldman, P Scheltens, P Aisen, S Andrieu, ...
Alzheimer's & Dementia 12 (3), 292-323, 2016
18902016
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
B Dubois, N Villain, GB Frisoni, GD Rabinovici, M Sabbagh, S Cappa, ...
The Lancet Neurology 20 (6), 484-496, 2021
7112021
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
HM Lanoiselée, G Nicolas, D Wallon, A Rovelet-Lecrux, M Lacour, ...
PLoS medicine 14 (3), e1002270, 2017
5482017
Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia
RER Slot, SAM Sikkes, J Berkhof, H Brodaty, R Buckley, E Cavedo, ...
Alzheimer's & Dementia 15 (3), 465-476, 2019
3632019
Pure alexia as a disconnection syndrome: new diffusion imaging evidence for an old concept
S Epelbaum, P Pinel, R Gaillard, C Delmaire, M Perrin, S Dupont, ...
cortex 44 (8), 962-974, 2008
3362008
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World …
P Lewczuk, P Riederer, SE O’bryant, MM Verbeek, B Dubois, PJ Visser, ...
The world journal of biological psychiatry 19 (4), 244-328, 2018
2602018
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study
B Dubois, S Epelbaum, F Nyasse, H Bakardjian, G Gagliardi, ...
The Lancet Neurology 17 (4), 335-346, 2018
2102018
EEG evidence of compensatory mechanisms in preclinical Alzheimer’s disease
S Gaubert, F Raimondo, M Houot, MC Corsi, L Naccache, J Diego Sitt, ...
Brain 142 (7), 2096-2112, 2019
1902019
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
A Vergallo, L Mégret, S Lista, E Cavedo, H Zetterberg, K Blennow, ...
Alzheimer's & Dementia 15 (6), 764-775, 2019
1502019
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020
H Hampel, S Lista, SJ Teipel, F Garaci, R Nisticò, K Blennow, ...
Biochemical pharmacology 88 (4), 426-449, 2014
1482014
Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum
WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ...
JAMA neurology 79 (3), 228-243, 2022
1412022
Detection of volume loss in hippocampal layers in Alzheimer's disease using 7 T MRI: a feasibility study
C Boutet, M Chupin, S Lehéricy, L Marrakchi-Kacem, S Epelbaum, ...
NeuroImage: Clinical 5, 341-348, 2014
1242014
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel
C Babiloni, X Arakaki, H Azami, K Bennys, K Blinowska, L Bonanni, ...
Alzheimer's & Dementia 17 (9), 1528-1553, 2021
1112021
Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total-tau, phosphorylated-tau, NFL …
H Hampel, N Toschi, F Baldacci, H Zetterberg, K Blennow, I Kilimann, ...
Alzheimer's & Dementia 14 (4), 492-501, 2018
972018
Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints
E Cavedo, PA Chiesa, M Houot, MT Ferretti, MJ Grothe, SJ Teipel, S Lista, ...
Alzheimer's & Dementia 14 (9), 1204-1215, 2018
902018
Free and Cued Selective Reminding Test–accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: a large-scale biomarker-characterized monocenter …
M Teichmann, S Epelbaum, D Samri, ML Nogueira, A Michon, H Hampel, ...
Alzheimer's & dementia 13 (8), 913-923, 2017
892017
Predicting the progression of mild cognitive impairment using machine learning: a systematic, quantitative and critical review
M Ansart, S Epelbaum, G Bassignana, A Bône, S Bottani, T Cattai, ...
Medical Image Analysis 67, 101848, 2021
862021
Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept
S Epelbaum, R Genthon, E Cavedo, MO Habert, F Lamari, G Gagliardi, ...
Alzheimer's & Dementia 13 (4), 454-467, 2017
822017
17q21. 31 duplication causes prominent tau-related dementia with increased MAPT expression
K Le Guennec, O Quenez, G Nicolas, D Wallon, S Rousseau, AC Richard, ...
Molecular Psychiatry 22 (8), 1119-1125, 2017
732017
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20